ABBV
AbbVie Inc.223.67
-3.78-1.66%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A flags street's neuro upside miss
Q&A largely reaffirmed prepared remarks' strong momentum but CEO Michael countered street models underestimating long-term upside, flagging neuroscience peaks over $5B apiece for Parkinson's and migraine franchises plus oncology ADCs like tmAbA. SKYRIZI IBD shares stayed rock-solid at 80% frontline Crohn's despite Tremfya, with category growth trumping competition. Psychedelic bradicilacin details popped: short hallucinations yield remission-like efficacy versus Spravato. Trinibot eyed to boost Botox share amid aesthetics slump. Street misses AbbVie's growth runway. Confident tone prevails; watch neuro execution.
Key Stats
Market Cap
395.31BP/E (TTM)
169.45Basic EPS (TTM)
1.32Dividend Yield
0.03%Recent Filings
8-K
AbbVie closes $6B notes
AbbVie closed its $6.0B notes offering on March 4, 2026, issuing senior floating-rate notes due 2028 alongside fixed-rate tranches—3.775% 2028s ($1.5B), 4.125% 2031s ($1.25B), 4.400% 2033s ($1.25B), 4.750% 2036s ($1.5B), 5.550% 2056s ($1.25B), and 5.650% 2066s ($0.5B). Unsecured notes rank equally with existing debt, featuring make-whole calls and standard covenants limiting liens. Use of proceeds not disclosed. Notes extend maturities smartly.
8-K
AbbVie prices $7B notes
10-K
FY2025 results
AbbVie drove FY2025 net revenues to $61.2B, up 8.6% y/y, with immunology stars Skyrizi ($17.6B, +50%) and Rinvoq ($8.3B, +39%) offsetting Humira's 49% plunge to $4.5B amid biosimilar erosion—yet Q4 momentum surged as these duo claimed 42% of sales. Neuroscience accelerated too, Qulipta rocketing 57% to $1.0B while Vraylar and Botox Therapeutic grew 11% and 15%; oncology's Elahere doubled to $690M. Gross margins held 70% despite $847M impairments, but $6.5B contingent liability markups crimped net earnings to $4.2B ($2.36 diluted EPS). Cash from ops hit $19B funding $11.7B dividends—up 5.5%—and $606M buybacks; revolver fully available. Biosimilar competition threatens quarterly immunology momentum.
8-K
AbbVie revenues up 8.6%
AbbVie posted full-year 2025 net revenues of $61.160 billion, up 8.6% reported, driven by immunology's $30.406 billion (up 14.0%) from Skyrizi ($17.562 billion) and Rinvoq ($8.304 billion), offsetting Humira's post-exclusivity drop. Adjusted diluted EPS hit $10.00 despite $2.76 per share IPR&D hit. Growth roared on. Issues 2026 adjusted EPS guidance of $14.37-$14.57.
8-K
Q4 IPR&D expense drags EPS
IPO
Website
Employees
Sector
Industry